INTRODUCTION: : Methylene blue is more widely available and less expensive than patent blue, with an apparently lower risk of anaphylaxis. OBJECTIVE: : The two dyes were compared regarding detection of the sentinel lymph node (SLN). METHOD: : A prospective, randomized trial involved 142 patients with invasive breast carcinoma. Sixty-nine (49.3%) assigned to patent blue (group A) and 71 (50.70%) to methylene blue (group B). Thirty-five patients (25.0%) were clinical stage III or IV; 55 (38.7%) had axillary lymph nodes affected; and 69 (49.3%) underwent neoadjuvant chemotherapy. Two patients were excluded because the dye type was not recorded. RESULTS: : Patients and tumor characteristics were similar in both groups. SLNs were identified in 47 women (68.1%) in group A and 43 (60.6%) in group B (p=0.35). SLNs were affected in 22 cases (51.2%) in group A and 21 (48.8%) in group B (p=0.62). The SLN was the only node affected in 12 cases (54.5%) in group A and six (33.3%) in group B (p=0.18). The time and degree of difficulty involved in identifying the SLN were similar in both groups. There were no complications or allergies. CONCLUSION: : Methylene blue performed as well as patent blue in identifying the SLN in breast cancer patients.
INTRODUCTION: : Methylene blue is more widely available and less expensive than patent blue, with an apparently lower risk of anaphylaxis. OBJECTIVE: : The two dyes were compared regarding detection of the sentinel lymph node (SLN). METHOD: : A prospective, randomized trial involved 142 patients with invasive breast carcinoma. Sixty-nine (49.3%) assigned to patent blue (group A) and 71 (50.70%) to methylene blue (group B). Thirty-five patients (25.0%) were clinical stage III or IV; 55 (38.7%) had axillary lymph nodes affected; and 69 (49.3%) underwent neoadjuvant chemotherapy. Two patients were excluded because the dye type was not recorded. RESULTS: : Patients and tumor characteristics were similar in both groups. SLNs were identified in 47 women (68.1%) in group A and 43 (60.6%) in group B (p=0.35). SLNs were affected in 22 cases (51.2%) in group A and 21 (48.8%) in group B (p=0.62). The SLN was the only node affected in 12 cases (54.5%) in group A and six (33.3%) in group B (p=0.18). The time and degree of difficulty involved in identifying the SLN were similar in both groups. There were no complications or allergies. CONCLUSION: : Methylene blue performed as well as patent blue in identifying the SLN in breast cancer patients.
Authors: Sreekar Devarakonda; Shawn Sam Thomas; Supriya Sen; Varghese Thomas; Reka Karuppusami; Anish Jacob Cherian; Pooja Ramakant; Deepak Thomas Abraham; Paul Mazhuvanchary Jacob Journal: Indian J Surg Oncol Date: 2021-01-16
Authors: H M Schouw; L A Huisman; H H Boersma; S Kruijff; Y F Janssen; R H J A Slart; R J H Borra; A T M Willemsen; A H Brouwers; J M van Dijl; R A Dierckx; G M van Dam; W Szymanski Journal: Eur J Nucl Med Mol Imaging Date: 2021-10-11 Impact factor: 9.236
Authors: Judith E K R Hentzen; Steven J de Jongh; Patrick H J Hemmer; Willemijn Y van der Plas; Gooitzen M van Dam; Schelto Kruijff Journal: J Surg Oncol Date: 2018-06-24 Impact factor: 3.454
Authors: Maximos Frountzas; Charalampos Theodoropoulos; Panagiotis Karathanasis; Christina Nikolaou; Constantinos G Zografos; Andreas Larentzakis; George C Zografos; Nikolaos V Michalopoulos Journal: Clin Case Rep Date: 2021-05-07